Pay in 4 interest-free payments of $5.67 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Ozempic and Wegovy were first put on the drug shortage list in August and May of 2022, respectively, because of a surge in demand
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma
2013;305(8):R88692
Weight loss of this magnitude has cascading health benefits
Meanwhile, sales of immunotherapy drugs such as Dupixent and Skyrizi, used for conditions like asthma, psoriasis, and rheumatoid arthritis, are expected to continue rising, following last year's trend
US$ 25.21
US$ 20.24
US$ 28.97
US$ 24.44
US$ 28.91
US$ 26.90
